Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- OM -41.1% (downside rev guidance), SGH -29%, BDC -14.1% (lowers Q3 guidance), IDT -3.2%, BLK -1.8%
Other news:
- SAVA -24% (co-developer of its Alzheimer's drug cited for misconduct according to Science.org; issues statement regarding an internal CUNY report leaked to the press)
- VIGL -5.6% (receives response letter from FDA re IND application for VG-3927)
- SGHT -2.1% (announces presentation of Phase I SAHARA trial)
- NUVL -1.7% (Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC)
Analyst comments:
- FTNT -3% (downgraded to Equal Weight from Overweight at Barclays)
- NFLX -1.9% (downgraded to Peer Perform from Outperform at Wolfe Research)
- ES -1% (downgraded to Neutral from Buy at Guggenheim)
- TSCO -0.9% (downgraded to Perform from Outperform at Oppenheimer)